André Luiz Costa e Silva

André Luiz Costa e Silva

Auto-generated profile, based on publicly available information

André Luiz Costa e Silva

Department of General Surgery, Heliopolis Hospital, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2025 in Techniques in Coloproctology
Verified
Journal Article
Open access
PDF file
BPB. F. Pompeu
B. F. Pompeu
PMP. Marcolin
P. Marcolin
FMF. I. L. C. B. Marques
F. I. L. C. B. Marques
GRGiulia Almiron da RSoares
Giulia Almiron da RSoares
ASA. L. C. e Silva
A. L. C. e Silva
FFF. B. Formiga
F. B. Formiga
Background There is ongoing debate regarding the benefits of extended mesenteric excision (EME) versus limited mesenteric excision (LME) in intestinal resection for Crohn’s disease (CD). Some studies suggest that EME may reduce surgical recurrence, which is defined as the need for reoperation due to disease complications or insufficient response to therapy, when compared with LME. This systematic review and meta-analysis aims to compare postoperative complications, surgical recurrence, and endoscopic recurrence in patients undergoing EME versus LME for CD. Methods MEDLINE, Cochrane, the Central Register of Clinical Trials, Scopus and Web of Science databases were searched for studies published through April 2024. Odds ratios (OR) with 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity was assessed with Cochran’s Q test and I2 statistics, with p-values < 0.10 and I2 > 25% considered significant. Statistical analyses were performed using R software, version 4.4.1. Results One randomized controlled trial (RCT) and five observational studies were included, totaling 4498 patients, of whom 1059 (23.5%) underwent EME and 3439 (76.5%) LME. EME was associated with a lower surgical recurrence rate (5% versus 15%; OR 0.31; 95% CI 0.12–0.84; p = 0.021; I2 = 47%). No significant differences were observed between EME and LME for overall complications, Clavien–Dindo ≥ 3 events, bleeding requiring transfusion, anastomotic leaks, intraabdominal abscesses, surgical site infections (SSIs), reoperations, readmissions, ileus, endoscopic recurrences, operative times, or hospital stays. Conclusions EME was associated with a significant reduction in surgical recurrence compared with LME, without differences in endoscopic recurrence or postoperative complication rates.

10 June 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
ASAndré Luiz Costa e Silva
André Luiz Costa e Silva
DCDiego Maia Diógenes Rabelo Caldas
Diego Maia Diógenes Rabelo Caldas
LSLaura Cristina Costa e Silva
Laura Cristina Costa e Silva
AGAlyne Barreto Mesquita de Goés
Alyne Barreto Mesquita de Goés
TSThais Cristina Loyola da Silva
Thais Cristina Loyola da Silva
IAIRAMI ARAÚJO-FILHO
IRAMI ARAÚJO-FILHO
To analyze the pathophysiological aspects of lupus mastitis (LM), clinical presentation, epidemiology, radiological and histological findings, and treatment, to disseminate it to the academic community and draw attention to this pathology as one of the differential diagnoses in the management of breast lesions in males, especially in the case of breast cancer in men. A literature review was done by searching scientific studies in the PubMed / Medline, Scopus, Scielo, Embase, Web of Science, and Google Scholar databases. Relevant scientifically validated studies related to lupus mastitis in men were selected. The analysis, review and selection of articles carried out in pairs, blindly and separately, based on the reading of the title and abstract, with a third reviewer in case of disagreement. The LM should be suspect in patients known to have lupus erythematosus who present painful breast nodules associated with skin changes. However, LM can be the initial manifestation of lupus and mimic, both clinically and imaging, malignant neoplasms. The histopathological diagnostic criteria are well-established, finding mainly hyaline fat necrosis and lymphoplasmacytic infiltrate. Treatment must be drug-based as invasive procedures can exacerbate the injury. Due to physiological and anatomical aspects, this condition can appear and evolve differently in men. The knowledge of this pathology is necessary to carry out the correct approach since the non-identification of the disease and its erroneous management can lead to complications and irreversible sequelae to the patient.

17 May 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
TSThais Cristina Loyola da Silva
Thais Cristina Loyola da Silva
PVPedro Vilar de Oliveira Villarim
Pedro Vilar de Oliveira Villarim
AGAlyne Barreto Mesquita de Goés
Alyne Barreto Mesquita de Goés
VMVitória Ribeiro Dantas Marinho
Vitória Ribeiro Dantas Marinho
NANatália Marcelino Araújo
Natália Marcelino Araújo
IAIRAMI ARAÚJO-FILHO
IRAMI ARAÚJO-FILHO
Hypertensive patients with COVID-19 are susceptible to complications of the disease, so this study aimed to analyze the action of drugs that act on Angiotensin (TA) in the presence of COVID-19 in comparison with other antihypertensives, as well as to identify the main ones. evidence on the subject presented so far. It is an integrative literature review containing 34 articles selected according to the inclusion criteria, between January / 2020 to February / 2021, in the PubMed, Embase, Scopus and Web of Science databases. The results do not show a causal relationship between the increase in COVID-19 infection and the use of RAAS inhibitors, but a possible protective effect of these against the severe manifestation of the disease due to the inhibition of the pro-inflammatory diseases of AT II. Thus, about ⅔ of the studies defended the continuity of use and the protection factor of RAAS blockers to the detriment of the other classes of antihypertensive drugs that do not modulate RAAS. It was found, then, that antihypertensive treatment should be maintained, as it does not worsen the prognosis in the face of Sars-CoV-2 infection. However, the studies are mainly observational and, therefore, cannot establish strong causal relationships. For this reason, robust randomized controlled trials are needed to better understand this topic.

17 May 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
VMVitória Ribeiro Dantas Marinho
Vitória Ribeiro Dantas Marinho
CVCamila Vilar Oliveira Villarim
Camila Vilar Oliveira Villarim
LSLaura Cristina Costa e Silva
Laura Cristina Costa e Silva
ASAndré Luiz Costa e Silva
André Luiz Costa e Silva
IAIrami Araújo-Neto
Irami Araújo-Neto
IAIRAMI ARAÚJO-FILHO
IRAMI ARAÚJO-FILHO
The rapid spread of coronavirus disease (COVID-19) worldwide urges the need for studies on the illness and its management. The COVID-19 infection leads to hypercoagulation due to inflammatory cytokine release and D-dimer increase in critically ill patients, resulting in pulmonary thromboembolism (PE) and venous thromboembolism (VTE) evolving to sepsis and death. The study evaluated the currently existing evidence on heparin administration in patients with severe COVID-19. An integrative literature review was done by searching for scientific studies in the PubMed, Scopus, Embase, and Web of Science databases. The analyzed studies showed that heparin use in critically ill patients could efficiently prevent thrombotic events and reduce the exacerbated inflammatory process. However, further investigation on the effect on patients is still needed. The use of heparin in critically ill COVID-19 patients has been prescribed increasingly by doctors. But its use has not yet had its outcomes well established in the literature. Therefore, deeper investigations and new research development are needed to clarify potential beneficial effects.